Radnor Capital Management LLC Invests $229,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Radnor Capital Management LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 2,733 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

Several other hedge funds have also made changes to their positions in the business. Catalina Capital Group LLC acquired a new stake in shares of Gilead Sciences during the third quarter worth about $323,000. Avidian Wealth Enterprises LLC raised its holdings in Gilead Sciences by 3.7% in the third quarter. Avidian Wealth Enterprises LLC now owns 8,612 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 310 shares in the last quarter. Crestwood Advisors Group LLC raised its holdings in Gilead Sciences by 10.1% in the third quarter. Crestwood Advisors Group LLC now owns 12,176 shares of the biopharmaceutical company’s stock valued at $1,021,000 after acquiring an additional 1,116 shares in the last quarter. Moloney Securities Asset Management LLC raised its holdings in Gilead Sciences by 5.4% in the third quarter. Moloney Securities Asset Management LLC now owns 25,975 shares of the biopharmaceutical company’s stock valued at $2,178,000 after acquiring an additional 1,326 shares in the last quarter. Finally, PDS Planning Inc raised its holdings in Gilead Sciences by 10.6% in the third quarter. PDS Planning Inc now owns 4,500 shares of the biopharmaceutical company’s stock valued at $377,000 after acquiring an additional 433 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several analyst reports. Cantor Fitzgerald raised their target price on shares of Gilead Sciences from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Thursday. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday. Truist Financial raised their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Eleven research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $90.05.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $97.90 on Friday. The firm’s fifty day moving average price is $84.58 and its 200 day moving average price is $74.67. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.32. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a market cap of $121.88 billion, a price-to-earnings ratio of 119.39, a price-to-earnings-growth ratio of 3.13 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the firm posted $2.29 EPS. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,437 shares of company stock worth $5,374,825 in the last three months. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.